Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.

Kley JT, Mack J, Hamilton B, Scheuerer S, Redemann N.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5924-7. doi: 10.1016/j.bmcl.2011.07.083. Epub 2011 Aug 9.

PMID:
21873051
2.

Synthesis of proline analogues as potent and selective cathepsin S inhibitors.

Kim M, Jeon J, Song J, Suh KH, Kim YH, Min KH, Lee KO.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3140-4. doi: 10.1016/j.bmcl.2013.04.023. Epub 2013 Apr 16.

PMID:
23639544
3.

Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain.

Zeng XF, Li WW, Fan HJ, Wang XY, Ji P, Wang ZR, Ma S, Li LL, Ma XF, Yang SY.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4742-4. doi: 10.1016/j.bmcl.2011.06.075. Epub 2011 Jun 23.

PMID:
21752639
4.

In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.

Venkatesh PR, Goh E, Zeng P, New LS, Xin L, Pasha MK, Sangthongpitag K, Yeo P, Kantharaj E.

Biol Pharm Bull. 2007 May;30(5):1021-4.

5.

Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6.

Shimamura K, Nagumo A, Miyamoto Y, Kitazawa H, Kanesaka M, Yoshimoto R, Aragane K, Morita N, Ohe T, Takahashi T, Nagase T, Sato N, Tokita S.

Eur J Pharmacol. 2010 Mar 25;630(1-3):34-41. doi: 10.1016/j.ejphar.2009.12.033. Epub 2010 Jan 4.

PMID:
20045404
6.

Novel benzoxazole inhibitors of mPGES-1.

Kablaoui N, Patel S, Shao J, Demian D, Hoffmaster K, Berlioz F, Vazquez ML, Moore WM, Nugent RA.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):907-11. doi: 10.1016/j.bmcl.2012.10.040. Epub 2012 Oct 16.

PMID:
23266122
7.

Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design.

Walker DP, Arhancet GB, Lu HF, Heasley SE, Metz S, Kablaoui NM, Franco FM, Hanau CE, Scholten JA, Springer JR, Fobian YM, Carter JS, Xing L, Yang S, Shaffer AF, Jerome GM, Baratta MT, Moore WM, Vazquez ML.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):1120-6. doi: 10.1016/j.bmcl.2012.11.107. Epub 2012 Dec 12.

PMID:
23298810
8.

Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.

Price S, Bordogna W, Braganza R, Bull RJ, Dyke HJ, Gardan S, Gill M, Harris NV, Heald RA, van den Heuvel M, Lockey PM, Lloyd J, Molina AG, Roach AG, Roussel F, Sutton JM, White AB.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9. Epub 2006 Oct 24.

PMID:
17107790
9.

Beta-lactam congeners of orlistat as inhibitors of fatty acid synthase.

Zhang W, Richardson RD, Chamni S, Smith JW, Romo D.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2491-4. doi: 10.1016/j.bmcl.2008.02.043. Epub 2008 Feb 19.

PMID:
18343106
10.

Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.

Wang X, Lin J, Chen Y, Zhong W, Zhao G, Liu H, Li S, Wang L, Li S.

Bioorg Med Chem. 2009 Mar 1;17(5):1898-904. doi: 10.1016/j.bmc.2009.01.050. Epub 2009 Jan 29.

PMID:
19223187
11.

Discovery and optimization of novel fatty acid transport protein 1 (FATP1) inhibitors.

Matsufuji T, Ikeda M, Naito A, Hirouchi M, Takakusa H, Kanda S, Izumi M, Harada J, Shinozuka T.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):5067-70. doi: 10.1016/j.bmcl.2012.05.130. Epub 2012 Jun 19.

PMID:
22749869
12.

5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a potent inhibitor for mammalian elongase of long-chain fatty acids family 6: examination of its potential utility as a pharmacological tool.

Shimamura K, Kitazawa H, Miyamoto Y, Kanesaka M, Nagumo A, Yoshimoto R, Aragane K, Morita N, Ohe T, Takahashi T, Nagase T, Sato N, Tokita S.

J Pharmacol Exp Ther. 2009 Jul;330(1):249-56. doi: 10.1124/jpet.109.150854. Epub 2009 Apr 9.

13.

Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the beta-ketoacyl reductase reaction.

Vázquez MJ, Leavens W, Liu R, Rodríguez B, Read M, Richards S, Winegar D, Domínguez JM.

FEBS J. 2008 Apr;275(7):1556-67. doi: 10.1111/j.1742-4658.2008.06314.x. Epub 2008 Feb 25.

14.

3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors.

Rivkin A, Kim YR, Goulet MT, Bays N, Hill AD, Kariv I, Krauss S, Ginanni N, Strack PR, Kohl NE, Chung CC, Varnerin JP, Goudreau PN, Chang A, Tota MR, Munoz B.

Bioorg Med Chem Lett. 2006 Sep 1;16(17):4620-3. Epub 2006 Jun 19.

PMID:
16784844
15.

Potent and novel 11β-HSD1 inhibitors identified from shape and docking based virtual screening.

Xia G, Xue M, Liu L, Yu J, Liu H, Li P, Wang J, Li Y, Xiong B, Shen J.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5739-44. doi: 10.1016/j.bmcl.2011.08.019. Epub 2011 Aug 8.

PMID:
21873057
16.

Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening.

Zheng Z, Parsons JB, Tangallapally R, Zhang W, Rock CO, Lee RE.

Bioorg Med Chem Lett. 2014 Jun 1;24(11):2585-8. doi: 10.1016/j.bmcl.2014.03.033. Epub 2014 Apr 2.

17.
18.

Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase.

Gorla SK, Kavitha M, Zhang M, Chin JE, Liu X, Striepen B, Makowska-Grzyska M, Kim Y, Joachimiak A, Hedstrom L, Cuny GD.

J Med Chem. 2013 May 23;56(10):4028-43. doi: 10.1021/jm400241j. Epub 2013 May 13.

19.

Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.

Ibrahim MA, Johnson HW, Jeong JW, Lewis GL, Shi X, Noguchi RT, Williams M, Leahy JW, Nuss JM, Woolfrey J, Banica M, Bentzien F, Chou YC, Gibson A, Heald N, Lamb P, Mattheakis L, Matthews D, Shipway A, Wu X, Zhang W, Zhou S, Shankar G.

J Med Chem. 2012 Feb 9;55(3):1368-81. doi: 10.1021/jm201533b. Epub 2012 Jan 24.

PMID:
22214363
20.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF.

J Med Chem. 2003 Apr 24;46(9):1627-35.

PMID:
12699381
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk